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Wound-dressing performances are affected by exudate viscosity, resistance to
flow because of gravity, and bodyweight loads, the level of which is related to
the body position. Here, we focussed on two dressing properties:
(a) Sorptivity—the ability of dressings to transfer exudate away from the
wound bed by capillary action—and (b) Durability—the capacity of dressings
to maintain their integrity over time and during their removal. Both properties
are critically important for avoiding further tissue damage but require the
development of new laboratory tests for their measurement. A computer-
controlled phantom of an exuding sacral pressure ulcer has therefore been
developed and used to compare the performances of Exufiber (Mölnlycke
Health Care) vs an alternative market-leading dressing. Sorptivity was deter-
mined using weight tests, and durability was measured through tensile tests of
the used dressings. For a supine configuration, the Exufiber dressing demon-
strated three times higher sorptivity and better durability, withstanding five
times greater strain energy than the other product before failure occurred. This
work paves the way for quantitative, standardised testing of dressings in all
aspects of exudate management. The reported tests are further suitable for test-
ing dressing combinations or how dressings interact with negative pressure
wound therapy.
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1 | INTRODUCTION
Pressure ulcers (PUs), also known as pressure injuries in
the United States, Canada, and Australia, are a common
complication of prolonged bed rest or sitting.1-3 It has
been established in numerous studies that PUs are a
cause of morbidity, mortality, pain, and reduced health-
related quality of life. Substantial direct (eg, treatment
and rehabilitation) and indirect (eg, potential litigation
and insurance) expenditure can also be incurred through
the development of a PU. In their early stages of develop-
ment, PUs stimulate the innate inflammatory response of
the immune system to increase the vascular permeability
around the site of tissue damage. This enables extravasa-
tion and infiltration of immune system cells (leukocytes)
to the damaged tissue and, consequently, results in exu-
date leakage from the vasculature surrounding the
wound.4-7 Exudate is a serum-based fluid with a dynamic
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composition of neutrophils and proteins, which typically
correlate to the healing phase, presence of pathogens,
and the overall severity of the specific wound. A mildly
moist wound environment is needed for adequate
healing8 as the exudate facilitates transport of essential
nutrients, as well as immunological factors, to the wound
bed8,9; stimulates fibroblast and endothelial cell prolifera-
tion10; and improves epithelisation.11,12 Exudate also acts
as a buffer to maintain an adequate pH environment, for
example, after exposure to bacterial infections.13 Exudate
secretion in a wound is, therefore, not only normal but
also has a crucial role in the healing process. However,
excessive exudate amounts may interrupt the healing
cycle or cause cytotoxicity. The exudate may also become
the transport medium for bacteria growing in the wound
bed, carrying pathogens to newly regenerated tissues in
the wound bed or to adjacent, non-wounded tissues.14
Accordingly, it is commonly accepted that wound exu-
date should be absorbed or retained to an adequate extent
by dressings to support the healing process and protect
skin and non-injured tissues surrounding an existing
PU. Gelling fibre dressings, also referred to here as pri-
mary dressings, are designed for these purposes.
Historically, gelling fibre dressings have been com-
posed of sodium carboxymethyl cellulose (CMC),
strengthening cellulose fibres, and other blended super-
absorbent materials.9,15-17 More recently, dressings con-
sisting of a non-woven pad or ribbon made from very
tightly entangled polyvinyl alcohol (PVA) fibres have
become available.18 This type of dressing locks fluids that
are absorbed into the dressing structure; the dressing
then swells and takes the form of a gel, which ideally
conforms to the wound cavity shape. The transformation
of the dressing from dry state to an absorptive state
assists in maintaining a moist environment in the wound
bed. This moist condition is required for the formation of
healthy granulation tissue, as explained above. In a good
treatment dressing, the retention of exudate in the dress-
ing structure occurs so that the exudate levels are con-
trolled, which in turn also helps to reduce the risk of
peri-wound maceration. After application of the gelling
fibre primary dressing to the wound cavity, a secondary
larger dressing is applied over the primary dressing to
absorb excess exudate, protect the wound from becoming
overly dry, maintain a physiological temperature, and
protect the wound from further mechanical trauma and
exposure to environmental pathogens.
As with any wound dressing, the performances of gel-
ling fibre dressings are primarily a function of the dress-
ing technology, that is, the specific material composition
and micro-architectural arrangement of the fibres and
superabsorbent elements, which determine the modes of
action of the dressings and their effectiveness.
Nonetheless, in any real-world clinical scenario, the
dressing structure always interacts with the patient and
the individual wound characteristics, as well as the spe-
cific environment acting on the wound (eg, the support
surface for a non-off-loaded wound and the forces and
microclimate conditions that develop there). The clinical
protocol and the practice of care further impact dressing
performance.
For example, a certain viscosity level of the exudate,
which is correlated with protein content and often associ-
ated with wound infections, can affect the exudate uptake
rate of the dressing. A slow absorbance process in the
dressing, because of a high exudate viscosity level, will
increase the risk of exudate backflow into the wound bed
and, thereby, pooling of the exudate in the wound cavity,
resulting in excessive wound bed hydration and potential
skin maceration. Likewise, the body position of the
patient dictates the resistance to the exudate flow by
gravity. Furthermore, any bodyweight forces exerted on
the wound (in a non-off-loaded wound) can decrease the
effective volume of the dressing reservoir or perhaps even
cause a pressure-induced release of fluids locked in the
dressing. The phenomena of patient bodyweight forces
mechanically distorting the wound bed and squeezing
the dressing may amplify if a patient is repositioned;
repetitively moves spontaneously, for example, because
of spasms, seizures, or agitation19; migrates (slides) in
their bed as the head of the bed is elevated20; or is trans-
ferred between support surfaces, as well as in numerous
others clinical scenarios. Furthermore, throughout the
treatment period, dressings will be mechanically loaded
by clinicians during dressing changes.
With respect to the modes of action of wound dress-
ings, the classic “fluid retention” and “fluid manage-
ment” attributes are often mentioned by manufacturers
and are typically gauged in simple, non-realistic labora-
tory setups, rather than by means of clinically relevant
test configurations.21 Currently, the most commonly
accepted testing standard in this regard, used by many
companies in the dressing industry and also as the basis
for their commercial demos, is the British Standard
no. EN 13726 for the testing of primary wound dressings
(2002).22 In the above British Standard, retention tests of
dressings are conducted using distilled water rather than
more viscous fluids, which disregards the strong effect of
the exudate viscosity level on the flow through the dress-
ing micro-architecture and, thereby, on the fluid absorp-
tion rate and the effectiveness of fluid retention. Not only
do many clinicians recognise the viscosity of the wound
exudate as a major factor affecting their dressing selec-
tion decisions, the theory of fluid flow in porous media
identifies the viscosity of the flowing fluid as a funda-
mental parameter that characterises the flow.
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Furthermore, the aforementioned British Standard does
not consider other critical clinical factors such as the ana-
tomical, physical, and pathophysiological environment of
the wound (eg, if there is undermining and, if so, what
are the effects of the associated geometrical confinements
on the conformation of the dressing structure; potential
spatial and temporal variations in wound temperatures
and pH levels; roughness and adhesiveness of the wound
surfaces etc.). In some of the test protocols specified in
the above British Standard,22 for example, in its section 1
“Aspects of Absorbency,” there is no consideration of the
directionality of the exudate flow (from the wound bed
into the dressing and from the wet front to the dry aspect
of the dressing, as occurs in real-world conditions) as, in
these tests, dressing specimens are submersed instanta-
neously in fluid. Likewise, the regime of mechanical
loads applied on the dressing while it is being used (eg,
because of patient bodyweight forces that apply statically
or dynamically and the loads applied by clinicians in
pulling the dressing out of the wound cavity during dress-
ing changes) are not considered. The wear-and-tear
effects on the dressing because of prolonged duration of
use in the often-hostile wound bed environment are also
not accounted for. Consequently, the dressing tests com-
monly used by manufacturers and regulators (based pri-
marily on the above British Standard), such as tests
where dressing specimens are submersed in vessels con-
taining watery dyes, do not adequately represent the body
and wound environments. The complex physical fluid-
structure interactions that occur in wound dressings
applied to real wounds, which discharge viscous exu-
dates, cannot be considered in such simplified set-ups.
Specifically, a key fluid-structure interaction concept,
“sorptivity,” which is the capacity of a dressing structure
to transfer excessive exudate away from the wound bed
by capillary action, has not been addressed in the wound
care literature to date. In addition, the durability of a
dressing, defined as the dressing capacity to withstand
the aforementioned patient bodyweight forces and the
forces applied on the dressing during changes, so that the
dressing does not disintegrate within the wound over a
period of use and the gel does not fracture into particles
upon removal, is critical. These two important dressing
characteristics, sorptivity and durability, directly relate to
the potential for peri-wound maceration and possible
inflammatory foreign-body reaction to any retained
dressing debris and gel particles, respectively.
Importantly, despite the fact that gelling fibre dress-
ings made by different manufacturers are already in
extensive clinical use, there are no standardised and clini-
cally realistic laboratory tests, protocols, or studies to
assess the performances of these dressings in their clini-
cal wound environment, taking into account relevant
fluid-structure interaction phenomena. In particular, the
above-described sorptivity and durability of these dress-
ings have never been addressed, and appropriate tests for
these properties have not been proposed. We therefore
developed, for the first time in the literature, a simulated
experimental environment that is anatomically and pat-
hophysiologically representative of sacral PU wound bed
conditions to assess the function of primary dressings
and the synergy in action between a primary and second-
ary dressing. Use of this new robotic phantom of an exud-
ing sacral PU is exemplified here through a comparison
of the performances of two primary dressing types, with a
focus on the sorptivity and durability properties of the
two primary dressing products. The present method and
system are a significant innovation for evaluating all the
known aspects of exudate management, spanning from
efficacy research to design and product evaluation. In
particular, the bioengineering laboratory tests reported
here are versatile and, we believe, would be suitable for
testing any combination of wound filler materials and
secondary dressings, or the interaction of primary and
secondary dressings with various exudates, in consider-
ation of relevant clinical factors and practice.
2 | METHODS
2.1 | Phantom of an exuding sacral PU
We have designed, developed, and built a robotic phan-
tom of an exuding sacral PU, simulating an active
wound environment in an anatomically and pat-
hophysiologically realistic form (Figure 1A). This robotic
phantom includes a rigid plastic replica of the pelvic
bones and soft-tissue substitutes made of a two-
component silicone rubber (RTV615, Momentive Perfor-
mance Materials Inc., Waterford, New York), which is
cast in the shape of the buttocks of an adult male (with
normal body mass index, BMI). The stiffness of the afore-
mentioned silicone rubber material, that is, elastic modu-
lus of 2.5 MPa, was measured through uniaxial
unconfined compressive testing (Instron electromechani-
cal testing apparatus model 5944, Instron Co., Massachu-
setts). A cylindrical geometry has been carved into the
sacral region of the phantom, to a depth of 2.5 cm, which
exposed the (plastic) sacrum, thereby simulating a cate-
gory 4 PU. Within the above-mentioned cavity, we placed
a three-dimensional-printed custom-made component,
which simulates the exuding wound bed. This wound
bed simulator has a truncated conical shape (ie, a “crater
wound”) with a diameter of 4.5 cm superficially and a
maximum depth of 2 cm with respect to the adjacent
phantom surface (Figure 1B).
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To simulate the continuous secretion of exudate, a
spiral perforated irrigation tube was incorporated in this
“wound bed” and tunnelled through the phantom struc-
ture to connect to an electromechanical syringe pump
(Genie Plus model, Kent Scientific, Torrington, Connecti-
cut). This automated system allowed the release of
exudate-substitute fluids into the “wound bed” at con-
trolled, preset flow volumes and rates. The effective wet
surface of the simulated wound bed was 25 cm2. The
margins of the wound were not irrigated (the irrigation
depth was 2 cm). This simulated wound design, includ-
ing its effective wet area and irrigation depth, is clinically
consistent with highly exuding wounds and replicates
some deep sacral wounds observed by our clinician co-
authors (PA, NS). To achieve thermodynamic
similarity across experiments, we further positioned an
FIGURE 1 The robotic phantom of a sacral pressure ulcer and its control set-up, A, which forms an anatomically realistic automated
testing system for wound dressings, B, including an exuding “wound bed,” C, that can be treated by means of any (combination of) dressing
products and clinical protocols for laboratory testing purposes [Color figure can be viewed at wileyonlinelibrary.com]
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adjustable-distance infrared heating lamp directly above
the “wound bed” (Figure 1A), which facilitated adjust-
ment of the wound cavity temperature within a range of
31C to 35C, which has been reported for sacral PUs.23
Five thermocouples embedded along the “wound bed”
perimeter were used to verify a limited range of “wound”
temperatures of 33C ± 2C (mean ± SD)
circumferentially.
2.1.1 | Exudate substitute fluids
We developed a safe and reproducible exudate substi-
tute fluid formula (for use with our robotic phantom
system), which facilitates control of fluid viscosity and
pH levels so that they adequately represent the physi-
cal characteristics of native exudate fluids. Specifically,
food-standard Xanthan gum powder at a concentration
of 0.01%, 0.05%, 0.1%, 0.15%, or 0.2% is mixed with dis-
tilled water, which results in a range of fluid viscosi-
ties, from watery to thick exudate substitutes (the more
viscous slough exudate types, which contain proteina-
ceous tissues, fibrin, neutrophils and bacteria, are clini-
cally associated with inflamed and likely heavily
infected wounds).8 It should be noted that rheological
properties of human wound exudates, and quantitative
(numerical) data of exudate viscosities in particular,
have not been reported in the literature so far. Specifi-
cally, while qualitative and descriptive clinical termi-
nology, using wording such as “thin,” “watery,”
“thick,” “sticky,” “creamy” etc.,8,24 is routinely being
used by health care professionals to categorise exudate
viscosities in their wound assessments,25 quantitative
physical and engineering measurements of exudate vis-
cosity data are currently absent from the literature.
Accordingly, we have developed our artificial exudate
fluids to have viscosity properties in the same range of
other human biological fluids (including protein-rich
fluids) for which quantitative (numerical) viscosity
data are available in the literature. The list of these vis-
cosity values that have been reported, for example, for
human blood plasma, whole blood, breastmilk, tears,
saliva, and gastrointestinal and respiratory mucus, are
summarised in Table 1. For example, Xanthan gum
concentrations of 0.01%, 0.05%, and 0.10% in our exu-
date fluid replica result in artificial exudate viscosities
of 0.006, 0.06, and 0.24 Pas, respectively. The first
value corresponds to the viscosity of whole blood,
whereas the second and third values define much of
the range of gastrointestinal mucus viscosities. Overall,
our artificial exudate viscosity property is adjustable
throughout 2/3 of the viscosity range that is charac-
teristic of human biological fluids (Table 1).
After preparing the fluids using the above-listed
Xanthan gum concentrations, their consistency was first
evaluated and confirmed by our nursing expert co-
authors (PA, NS) based on their clinical experience and
were approved to be qualitatively representative of real-
world exudates.8 Next, quantitative laboratory evalua-
tions of the exudate replica fluids were conducted, by
means of rheology tests, to verify that the resulting fluid
viscosities were representative of the human biological
fluid viscosity range and to further characterise this
substitute-exudate formula (rheometer model AR-G2, TA
instruments, New Castle, Delaware). The above rheologi-
cal testing demonstrated a shear thinning behaviour of
the exudate substitutes with an increase in the shear rate
(Figure 2A), which is consistent with the testing of bio-
logical mucus fluids.32,33 Of note is that the present artifi-
cial exudate formula, reported here for the first time in
the literature, avoids the use of potentially infectious nat-
ural biological materials such as animal blood plasma or
serum, which can potentially be used to simulate exu-
dates in laboratory experiments or product demonstra-
tions. The resulting fluids had densities of 1.01 to
1.05 g/cc (ie, mildly denser than water, which overlaps
the range of blood plasma to whole blood densities) and
viscosities in the range of 0.006 to 0.71 Pas (Figure 2B),
depending on the specific Xanthan gum concentration.
The pH of the exudate substitute was determined as
acidic and equalled 5 for all the presently reported experi-
ments, which is typical for non-infected wounds13,34;








Water 0.71 × 10−3 26
Blood plasma 1.24 × 10−3 27,28
Whole blood 5.99 × 10−3 28
Brest milk 2-9 × 10−3 29
Tears 1.5-9 × 10−3 30
Saliva 5-25 × 10−3 31
Gastrointestinal mucus 6-84 × 10−3 32,33
Gastrointestinal mucus of
patients with a duodenal
ulcer
2.5-30× 10−2 33
Respiratory mucus 12-15 32
Nasal mucus 1.3-46 32
Cervicovaginal mucus 20-80 32
Respiratory mucus in cystic
fibrosis patients
Up to 110 32
198 LUSTIG ET AL.
however, this “exudate” property can be adjusted as
needed, for example, be made more acidic through the
gradual addition of 5% standard-food vinegar. Finally,
three drops of green food dye were added to each 50 mL
of the exudate substitute for visualisation of the spread of
the fluid in the “wound bed” and the tested dressing
products.
2.2 | Simulated treatments
Prior to applying dressing products to the simulated
sacral wound, we weighed both the primary dressings
(we used Exufiber [Mölnlycke Health Care AB,
Gothenburg, Sweden] with PVA fibres) and an alterna-
tive existing market-leading product with CMC fibres,
referred to here as the “other product” and secondary
multi-layer absorbent foam dressings (Mepilex Border
Sacrum = MBS, Mölnlycke Health Care AB, which has
been used in all the present trials). Expert clinicians (co-
authors PA, NS) guided the cutting and fitting of the two
primary dressing products into the “wound bed” to care-
fully fill the wound cavity, following which the wound
was covered with a secondary dressing as per the instruc-
tions for use provided by the manufacturers. The robotic
phantom was then positioned prone, supine, or in a side-
lying (lateral) position (as the specific test required;
details follow), and the system was activated with the fol-
lowing set of parameters: exudate density = 1.03 g/cc;
exudate viscosity = 0.23 Pas (associated with a Xanthan
gum concentration of 0.1%); flow rate = 0.08 or 0.12 mL/
cm2/hour, corresponding to medium-exuding or highly
exuding wounds, respectively35; and simulated use
time = 5 hours (“short use”) or 15 hours (“long use”).
While the aforementioned use times are shorter than
some reported real-world use times for wound dressings
(ie, once a day or even less often for home care), the
selected use times were specifically chosen so that dress-
ing products could be tested before they were completely
saturated (soaked) with the simulated exudate and before
material ageing had progressed to extreme (which is
conservative bioengineering testing). In addition, for
completeness of the experimental work and to verify
the generalisability of our present results to silver ion (Ag
+)-containing antimicrobial dressings,36 we repeated one
experimental set where the phantom was in the supine
position, using the equivalent Ag +-type dressing for
each of the tested products, that is, we tested the Exufiber
Ag + vs the Ag + version of the same market-leading
competitive primary dressing. Each trial (with a given
combination of the above experimental parameters) was
repeated at least four times (the specific number of repe-
titions differed across the test types, as reported hereun-
der, and is provided in the captions of the graphical data
where appropriate, for each test type).
2.3 | Testing of the dressings post-
simulated use
2.3.1 | Retention and fluid distribution
tests
Following simulated use, both the primary and second-
ary dressings were removed in a manner in which an
experienced clinician would remove them from a real-
world wound, based on guidance and rigorous hands-
FIGURE 2 Rheology test data for the exudate substitute
fluids: A, Viscosity vs the shear rate and B, viscosity at a preset
unity (1/s) shear rate for different Xanthan gum concentrations in
distilled water
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on training provided by our clinician co-authors (PA,
NS) (Figure 3A). The used dressings were then weighed
again. The free exudate substitute in the wound bed
was collected (Figure 3A). The total exudate volume
(TEV) was then calculated by summing the volume of
fluid in the primary dressing (wet minus dry weight,
divided by respective “exudate” density ρ = 1.03 g/cc),
the secondary dressing, and the free exudate substitute
in the wound bed. The latter, calculated TEV was
always mildly lower (by 15% on average) than the theo-
retical TEV, which is the product of the flow rate and
simulated use time, because of evaporation and residual
fluid in the tubing. We determined the fluid retention
in each (primary or secondary) dressing as the wet-dry
weight difference divided by the aforementioned
exudate fluid density. We further evaluated the fluid
distribution between the primary and secondary dress-
ings per each trial as the ratio of the fluid volume
retained in each dressing over the calculated TEV in
the respective trial.
2.3.2 | Material strength tests
Each primary dressing specimen was tested for tensile
strength immediately post-simulated use (Instron electro-
mechanical testing apparatus, model 5944 Instron Co.),
following the ASTM D-882-02 standard. A load cell with
a 2 kN capacity was used for these tests. Dressing speci-
mens prepared according to the above testing standard
FIGURE 3 Fluid retention and
distribution testing of dressing
products: A, post-simulated use, exudate
substitute is absorbed in the primary
dressing (shown) and a secondary
dressing (not shown); some free exudate
typically resides in the simulated wound
bed. B, Fluid retention (reported as
percentage of total exudate volume) after
15 hours of simulated (long) use in a
prone position (N = 10 test repetitions
per dressing configuration). C, Fluid
distribution between the primary and
secondary dressings after 5 hours of
simulated (short) use in supine and side-
lying positions (N = 4 test repetitions
per dressing configuration). The error
bars are the SDs, and an asterisk
indicates a statistically significant
difference in outcome measures
(P < .05) [Color figure can be viewed at
wileyonlinelibrary.com]
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were stretched at a 50-mm/min deformation rate until
ultimate failure (rupture) occurred. Stress-strain
curves were then plotted based on the resulting force-
deformation data, and the strain energy density (SED),
that is, the area under the stress-strain curve required to
reach the first major failure point (defined as a minimum
of 10% decrease in the stress level), was calculated using
a dedicated computer code (MATLAB software suite ver.
R2019b, MathWorks, Inc., Natick, Massachusetts). Selec-
tion of the SED as a scalar measure of the failure strength
of each primary (used) dressing was motivated by the
usage of the SED as a well-established failure criterion in
numerous material studies and in multiple engineering
fields.37
2.4 | Statistical analysis
We report here the descriptive statistics (mean ± SD) for
all outcome measures. Unpaired, two-tailed t tests were
conducted (Microsoft Office Professional, Excel 2016) to
detect potential statistically significant differences in fluid
retention capacities and distributions, as well as SED-to-
failure, between the two dressing configurations
(Exufiber + MBS vs other product + MBS). The statistical
significance level was set as P < .05.
3 | RESULTS
The retained fraction of total exudate fluid volume and
the distribution of fluids between the primary and sec-
ondary dressings post-simulated use, for the two primary
dressing products that have been tested here, are shown
in Figure 3. A comparison of the retention performances
between these tested products after 15 hours of simulated
use in a prone position (Figure 3B) demonstrated supe-
rior performances of the Exufiber dressing over those of
the other market-leading product. Specifically, when the
phantom was used in its prone configuration, gravity pul-
led the irrigated exudate (which was delivered in these
experiments at a rate of 0.08 mL/cm2/hour) downwards
to the bottom of the wound bed. From a clinical perspec-
tive, this would imply a risk of pooling of exudate fluids
at the depth of the wound bed and, thereby, potential
over-hydration of the wound. In this testing scenario, the
Exufiber dressing retained 54.4% ± 2.5% (mean ± SD) of
the simulated exudate compared with the retention of
51% ± 4% of the fluid in the other product, which was a
statistically significant difference (P < .05, Figure 3B).
Worth noting is that, in this prone position, the percent-
age of non-retained exudate, about 50%, is relatively high
as the fluid would naturally stay at the bottom of the
wound bed, and so, a primary dressing would require
effective “capillary action,” that is, that the exudate
would flow in the narrow spaces of the dressing
micro-architecture in opposition to gravity. In that
aspect, Exufiber demonstrated better capillary action,
which is likely propagated by its tightly entwined PVA
fibres. This is in stark contrast to the CMC-composed gel-
ling fibre dressing, which appears to be occlusive. In
other words, given that both dressing products were
tested in exactly the same geometrical, fluid flow, and
temporal configurations, the sorptivity (ie, the capacity of
the dressing structure to absorb liquid by capillarity38) is
significantly greater for the Exufiber dressing.
Given the present data and explanations, it is not sur-
prising that, in our prone configuration experiments
described above, we could not identify a sufficiently mea-
surable amount of exudate fluids in the secondary MBS
dressings (for either primary dressing type). The reason
for this is that capillarity per se is insufficient for over-
coming gravity and pushing the large exudate fluid mass
all the way from the irrigation site (near the bottom of
the wound bed) up to the level of the surface of the
“prone” body. To determine if increasing the rate of the
exudate irrigation—still in a prone position—would lead
to some fluid retention in the secondary MBS dressing,
we repeated the above set of experiments after adjusting
the exudate flow rate to 0.12 mL/cm2/hour (for experi-
mental sessions of 15 hours), representing a highly exud-
ing wound. Increasing the exudate flow rate as above did
cause a mean of 2.7% of the total exudate mass to accu-
mulate in the secondary MBS dressing in the trials where
Exufiber was the primary dressing (for N = 3 trial repeti-
tions), with an indistinguishable difference in total
retained vs non-absorbed fluid between the product
types. However, the MBS consistently remained dry
where the other primary dressing product was used. This
additional set of experiments therefore further confirmed
the good sorptivity of Exufiber.
In contrast to the prone experimental configuration
studies, positioning the phantom system supine, as in a
non-offloaded sacral wound, would cause gravity to clear
exudate away from the bottom of the wound bed and
thereby, theoretically, lower the risk of maceration in this
aspect. Nevertheless, in a real-world clinical scenario,
loading the wound with bodyweight forces would also
subject the wound bed and peri-wound tissues to
sustained large tissue deformations, which are likely to
cause additional deformation-inflicted tissue damage
and, furthermore, secondary and tertiary inflammatory
and ischaemic damage, respectively.4,5,39 The decision of
whether to position a patient prone or supine (or in
another posture) would eventually be based on clinical
judgement, depending on many other vital medical
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parameters. For example, such decisions would be dic-
tated by the need to achieve better tissue oxygenation by
ventilating acute respiratory distress syndrome patients
prone or by placing patients on extracorporeal membrane
oxygenation treatment where they must be positioned
supine. In this context, it is important to test the perfor-
mances of wound dressings in a simulated supine pos-
ture, as well as in other potential and common body
positions, for example, the lateral posture. Given that the
drainage of excess exudate from a sacral wound occurs
more naturally in a supine posture, because of the action
of gravity, we conducted shorter, 5-hour experiments for
supine and lateral phantom configurations.
Accordingly, the fluid distribution between the pri-
mary and secondary dressings was measured after
5 hours of simulated use in supine and lateral positions,
where an exudate flow rate of 0.12 mL/cm2/hour was
set. The results from these experiments, shown in
Figure 3C, demonstrate that, as expected, a substantial
portion of the TEV, 21% to 73%, reaches the secondary
MBS dressing at the surface of the “body” (which is at
least 10 times the amount of fluids that were absorbed in
the secondary dressing in the prone experiments). More-
over, when the capillarity of the dressing structures was
fully aligned with the direction of gravity forces (as in
the supine phantom configuration) or was partially
aligned with gravity (for the lateral experiments), the dif-
ferences in performances of the primary dressings
became even more apparent. For the supine position, the
Exufiber dressing was able to retain 40% of the exudate
but, importantly, deliver the other 60% of the fluid away
from the wound bed, into the secondary MBS dressing.
In comparison, the other product was only able to trans-
port 21% of the fluid to the MBS dressing, which clini-
cally implies that more exudate remains within the
wound bed (P < .05, Figure 3C, left panel). In agreement
with the above observations, the total retained fluid for
this experimental set was 99% ± 0.04% for the Exufiber
dressing, compared with 96% ± 0.2% for the other prod-
uct (P < .05). Consistently, for the lateral position, the
Exufiber dressing retained 27% exudate but, again, trans-
ferred the other 73% of the fluid into the secondary MBS
dressing; the other product only transported 52% of the
fluid to the secondary MBS dressing (P < .05, Figure 3C,
right panel). In related observations, in three of five trials
performed with that other product in the lateral position,
some fluid leakage was observed, likely because of exces-
sive build-up of fluids in the wound bed; this never
occurred in the trials conducted using the Exufiber
+ MBS dressing combination. The total retained fluid
data for this experimental set underpins the superior
absorbency of the Exufiber dressing, which achieved
93.8% ± 1.3% retained fluid, compared with only 78% ±
18% retained fluid in the other product (leakage around
the primary dressing caused the relatively high variabil-
ity in the latter result).
Consistent with the non-silver dressing data, the
Exufiber Ag + dressing retained 51% of the exudate fluid
and transferred the other 49% into the secondary MBS
dressing, whereas the comparator silver-containing pri-
mary dressing transported only 31% of the fluid to the
secondary dressing (N = 5, P < .05).
The tensile tests of the used primary dressing prod-
ucts demonstrated a considerably distinct failure pattern.
The used Exufiber dressing was shown to be substantially
more extensible and structurally stable post-use com-
pared with the other product, which demonstrated tears
in its fibres early during the course of stretching
(Figure 4). The stress-strain data of the two products
(Figure 5A) further showed that the Exufiber dressing
can withstand strains of up to 200% without any appar-
ent loss of fibre integrity, whereas in the other primary
dressing product, the first fibres failed at strains as low as
37%, with more substantial early failures occurring at
45% strain (a “peak & drop” behaviour, where additional
FIGURE 4 Material strength tests comparing the failure
behaviours of the two primary dressing types evaluated here (each
photographed during a representative trial). The failure region at the
time point preceding the ultimate failure has been magnified for each
dressing type to show the structural integrity and fibre rupture state
[Color figure can be viewed at wileyonlinelibrary.com]
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fibre failure continued thereafter and repeated until ulti-
mate failure occurred; Figure 5A). The latter failure pat-
tern continuously fractures the gel, and hence, any
individual fibre failure events may release dressing
micro-particles into the environment. Calculations of
SED data from the acquired experimental stress-strain
curves indicated that the Exufiber dressing is five times
more endurable than the other primary dressing product
and would therefore be able to withstand (statistically)
significantly greater mechanical energy before its fibres
would fail (P < .05, Figure 5B).
4 | DISCUSSION
Exudate fluids play a key role in wound healing and tis-
sue repair. The wound bed needs to be mildly moist for
adequate healing to occur. The moisture in the wound
bed facilitates cell proliferation, migration, and growth,
as well as the synthesis of collagen towards tissue repair.
However, excessive exudate volumes may disrupt the
healing cycle and be an irritant, toxic, or infectious to
adjacent tissues. Excessive exudate should therefore be
retained in therapeutic dressings to support healing. Gel-
ling fibre dressings are designed for the above purpose.
Historically, gelling fibre dressings have typically been
made of CMC fibres, but now, primary gelling fibre dress-
ings based on PVA fibres are available. The PVA fibre-
based dressings are intended to continuously absorb and
lock in secreted exudates so that the fluid level in the
wound bed is controlled. It is surprising, given the exten-
sive use of wound dressings, that bioengineering work in
this field is poor and sparse with respect to other fields of
medical applications. In particular, while a small number
of laboratory tests is used to gauge fluid management
properties of treatment dressings,40* current testing
methods may not necessarily reflect the impact of real-
world factors on dressing performances, including, for
example, the effects of treatment protocols, positioning of
patients, time and clinical technique of dressing changes,
exudate properties, etc. Our novel laboratory method and
system facilitates experiments that expose dressings to
exudate-like fluids at the chemical, mechanical, thermo-
dynamic, and use conditions, which replicate real-world
settings. This then facilitates objective, quantitative, and
standardised evaluations of dressing products, and
thereby systematic comparisons of dressing perfor-
mances, while effectively accounting for the clinical con-
siderations that apply in practice.
The primary mechanism of action for gelling fibre
treatment dressings is capillary motion, where exudates
(also carrying the biological debris) are being lifted and
moved away from the wound surface through a capillary
effect.41 The ability of an absorbent material to transfer a
certain viscous fluid by capillary motion through the






where V is the cumulative volume of the liquid absorbed
through a cross-sectional area A of the absorbent mate-
rial at time t (as long as the material is not fully satu-
rated), and S is the sorptivity of the absorbent material.














where d, γ, and μ are the density, surface tension, and vis-
cosity of the fluid undergoing the capillary uptake,
respectively; ε is the effective porosity of the dry
FIGURE 5 Determination of the strain energy density (SED)
to failure of the used primary dressings after 15 hours of simulated
(long) use: A, representative stress-strain curves for the two
dressing types, showing continuity associated with robustness of
the Exufiber dressing, vs discontinuity because of multiple fibre
rupture events for the “other product.” B, The corresponding SED
to failure of the two dressing types (N = six test repetitions per
dressing configuration). The error bars are the SDs, and an asterisk
indicates a statistically significant difference in outcome
measures (P < .05)
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absorbent material; λ is the average tortuosity factor of
the capillaries (tortuosity is the ratio of the length of a
flow path between two points in the absorbent material
to the corresponding straight-line distance and, hence,
for all practical materials, λ > 1); r is the average pore
radius; and θ is the contact angle of the interface between
the liquid and pore walls. Thus, referring to the right-
hand side of Equation (2), the first term (from left to
right) only contains parameters that characterise the liq-
uid, whereas the second term consists of variables of the
absorbent material microstructure, and the third term
represents the interface between the absorbent material
and liquid. Worth noting is that, from a medical-clinical
perspective, some of the parameters in Equation (2)
depend on the environment and microclimate of the
wound, for example, the surface tension (γ) and viscosity
(μ) of the exudate fluid depend on the temperature of the
wound bed. The tortuosity (λ) depends on the fluid pres-
sure gradient, which is a function of the sustained
mechanical loads applied onto the wound (associated
with the body position). Taken together, Equations (1)
and (2) indicate that an exudate fluid with a lower viscos-
ity would cause greater sorptivity and, hence, more exu-
date transfer into the dressing through capillary action;
however, that can be counteracted by a low porosity (ε)
or small pores (r) in the dressing material. This is an
important and illustrative analytical example that high-
lights the reasoning for the present experimental model
for testing dressings, which accounts for these complex
physical interactions.
With respect to the clinical use of treatment dressings,
good sorptivity of a primary dressing is critical in clearing
excess exudate fluids away from the wound bed, espe-
cially if a secondary dressing is used. This dressing prop-
erty is even more crucial when the sorptive material
(with capillary action) should perform against gravity
forces as some patient positions may dictate. Dressings
with poor sorptivity, even ones with a high theoretical
retention capacity, that is, having a high saturation
threshold tested in sterile conditions, will have a limited
effective retention capacity when used in practice, where
opposing gravity forces will prohibit such dressings from
reaching their full saturation potential. Good total fluid
handling of a dressing should therefore include sorptivity
through capillarity, that is, adequate fluid transfer from
the primary treatment dressing to a secondary dressing,
as well as sufficient retention reservoirs, using the capaci-
ties of both dressings. Not allowing effective transfer of
wound fluids between the primary and secondary dress-
ings will cause a “plugging effect.” The plugging, if
occurs, will limit the maximal fluid volume absorbed in
the system of dressings (ie, the primary plus the second-
ary dressings), which should work synergistically to the
capacity of the primary dressing alone, and thus increase
the risk of the return of exudate to the tissues or leaks
that could cause maceration or secondary irritation and
provide a pathway into the wound for pathogens.
The exudate composition changes in correlation to
the wound-healing stage and severity, as well as because
of underlying conditions and chronic diseases, with a
physiological mechanism regulating immunological fac-
tors, that is, neutrophils and proteins in the wound bed.
Values of exudate viscosity and pH, as well as the TEV,
ultimately reflect these complex biological and patho-
physiological interactions at the wound level and the
whole-body system level. Viscosity ranges from that of
thin and watery fluid to that of a thick sticky mass, and
pH may be acidic or sometimes alkaline, being highly
influenced by the nature of the microbiome, that is, the
populations of the bacterial or fungal (eg, yeast, mould)
contaminations that typically exist in chronic wounds.44
This tight correlation makes wound exudate a key wound
parameter, defined as one of the “three continuums,”
namely, the wound-healing continuum, the wound infec-
tion continuum, and the wound exudate continuum,
used in the “wound management framework”25 for the
assessment of wound and patient's health status in a logi-
cal and systematic way. In clinical practice, exudate vol-
ume and consistency levels are being collected and
categorised periodically to determine improvement or
deterioration in wound status and to identify alteration
in the wound bioburden and development of infections,
which require careful consideration. The dynamic nature
of wound exudates translated into their viscosity, and the
known effects that viscosity (μ) has on capillary motion
in dressings, as formulated in Equation (2), make the vis-
cosity parameter (which is specific to the patient and the
wound-healing stage as explained above) an important
consideration when testing any treatment product
performances.
Patient positioning will also have a fundamental
effect on wound-dressing performances, as demonstrated
by our present data (Figure 3C). Patients with sacral PUs
will preferably have their wounds off-loaded, that is, in
prone or lateral positions, to alleviate the tissue stresses
formed because of the bodyweight loads and, thereby,
lower the risk for continued tissue deformation-inflicted
damage to the wound and its surroundings. Nevertheless,
in a real-world clinical scenario, other vital medical con-
siderations may exist that overweigh the need to off-load
the wound, making all possible lying positions (including
the supine position) relevant to the testing of sacral dress-
ings performances. Using our system to test dressing per-
formances while the phantom was used in a prone
configuration allowed us to evaluate the sorptivity of pri-
mary wound dressings, where the primary dressing is
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required to act against gravity forces in maintaining the
exudate balance in the wound and wicking excess fluids
away from the wound bed. An important observation is
that the percentage of exudate absorbed in the Exufiber
dressing for the above “prone” experiments is greater
with respect to the other product (Figure 3B). This could
only be achieved through better capillarity of the
Exufiber dressing, consequently clearing more excess
exudate from the simulated wound. Furthermore, the
Exufiber dressing facilitated superior fluid transfer to the
secondary MBS dressing compared with the other pri-
mary dressing, regardless of the body position
(Figure 3C). The “plugging effect” of the other dressing,
because of its limited capillarity and low sorptivity, is
clearly demonstrated in our results (Figure 3C) and was
consistent for even relatively high exudate flow rates set
in the robotic phantom system.
In supine and lateral positions (Figure 3C), gravity
forces “help” to clear exudate away from the wound bed
as fluids are naturally drained in the general direction of
the dressing. With that said, this downward exudate
motion also creates a large volume of exudate fluid for
the dressing to absorb and handle momentarily. Fluid
accumulated at the interface with the primary dressing is
being gradually absorbed, first by maximising the pri-
mary dressing capacity and, ultimately, by capillary
motion to reach the secondary dressing. Accordingly, the
fluid distribution between the primary and secondary
dressings strongly depends on the sorptivity level of the
primary dressing (Equation 2). The Exufiber dressing has
been shown to deliver higher fluid amounts to be ulti-
mately absorbed in the secondary dressing, which has
been consistent for the supine and side-lying body pos-
tures, as well as between the non-silver and silver ver-
sions of this dressing. The more fluid that is being
transferred to the secondary dressing, the better the pri-
mary dressing can absorb newly secreted exudate without
maxing out its capacity. In other words, good sorptivity of
the primary dressing enables the retention reservoirs of
both the primary and secondary dressings to be used. For
the other product that has been tested here, we observed
lower amounts of fluid delivered to the secondary dress-
ing (Figure 3C) and, as a result, unsurprisingly, some
leaking of the simulated exudate caused by the excessive
build-up of fluids. Of note is that, in a real-world sce-
nario, such leaking of excess exudate may cause peri-
wound maceration of the skin, secondary infections, or at
least skin irritation, which are all unwarranted. Another
noteworthy point is that posture had little effect on the
performances of the Exufiber dressing, which delivered
similar amounts of fluid to the secondary dressing in the
supine and side-lying experimental configurations
(Figure 3C). In contrast, the other primary dressing had
inferior sorptivity in the supine posture than in the lat-
eral lying position, which is not favourable as a dressing
should ideally maintain its performances independent of
the body posture.
Wound dressings are designed primarily to absorb
and retain fluids; nevertheless, it is crucial that the used
dressings maintain their mechanical strength and struc-
tural integrity to endure extraction forces that occur as
they are removed from a wound (eg, during dressing
changes) without leaving debris from the dressing mate-
rials in the wound bed. Any dressing debris left in the
wound bed may result in a “foreign body response,”45
which prolongs the inflammatory phase and, therefore,
delays the wound healing. The Exufiber dressing has a
robust and consistent micro-architecture, allowing it to
endure higher tensile and frictional forces (with SED that
is up to five times greater than the comparison;
Figure 5B), which a clinician may generate using forceps
during a dressing change manoeuvre (replicated in our
laboratory by means of an electromechanical testing sys-
tem; Figure 4). From the stress-strain curves produced
through these mechanical tests (Figure 5), we identified a
“rubber-like” material behaviour under tensile loading
for Exufiber, as opposed to a classic mechanical failure
pattern (“peak-and-drop”) for the other product, which
demonstrated poor mechanical strength. The mechanical
behaviour of the latter dressing, which contains oriented
woven fibres to reinforce it, has a directional stiffness
preference that results from its weave pattern. Our pre-
sent test data were obtained where the dressing was
stretched in a direction that aligns exactly with the orien-
tation of the structural fibres in the dressing. That is, we
performed our tests to represent the best-case scenario
for this dressing, where the reinforcing fibres take full
part in the mechanical loading, which is not necessarily
how a clinician would pull that dressing from a wound.
The images in Figure 4B document a clear-cut separation
of the dressing material component designed to provide
mechanical strength and structural support (ie, the rein-
forcing fibres) from the material component designated
to absorb fluids. As the absorbent material ingredient has
nearly no structural strength of its own, the risk of disin-
tegration of the dressing with pull-out or frictional forces
or a combination of both clearly increases during dress-
ings changes. While we did not see such breakdown of
the dressing material in the simulated wound bed (but
only afterwards, during the mechanical testing post-
simulated use; Figure 4B), we suspect that the reason for
this relates to a limitation of our experimental wound
system. Specifically, we surmise that the reason for the
dressing showing a “peak-and-drop” failure behaviour to
not fail already in the simulated wound bed is that our
wound surfaces were relatively smooth and non-sticky
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(3D-printed plastic), which is a simplification of the real-
world wound bed conditions. A native wound would
have relatively rough sticky surfaces and potential adhe-
sion sites with the primary dressing. Our mechanical test-
ing data (Figures 4 and 5) should therefore be interpreted
as demonstrating a much more likely breakdown of the
other dressing compared with Exufiber, where there is an
attempt to pull the dressing out of a rough or sticky
wound or when a part of the primary dressing is trapped
in or is rubbing against undermining or some other odd-
shaped deep cavity of a wound. Another limitation of the
present robotic phantom version may therefore be the
absence of undermining, which can be included in future
versions of the 3D-printed wound bed.
An additional potential future use of our novel
robotic phantom system is for moisture-vapour transpira-
tion (MVT) studies, particularly studies of the interaction
of MVT with the sorptivity of the tested dressings. Theo-
retically, a high MVT rate of a dressing would promote
the capillary action in that dressing against the wound
bed surface as a larger portion of the dressing volume
becomes unsaturated and, therefore, available for new
absorption of exudate fluids. Future work with our pre-
sent phantom system should explore these very complex
and coupled transport phenomena. It is also possible to
study how the MVT and sorptivity performances may
depend on the body core temperature of the patient
(which can be altered in our robotic phantom system), as
well as on the exudate flow rate and the ambient condi-
tions. The simulated ambient conditions may be selected
to represent different geographical climate variations or
characteristics of a clinical setting (eg, use of air condi-
tioning and the specific temperature adjustments in the
air-conditioning system) in order to predict how dress-
ings may behave in specific countries and medical
settings.
To summarise, a novel, active exuding sacral wound
simulator, which makes a “robotic phantom” for dressing
tests, has been developed and built to facilitate, for the
first time, complex experiments that expose dressings to
exudate-like fluids at the mechanical, thermodynamic,
and use conditions, which duplicate real-world care set-
tings. Using the above system, we compared the perfor-
mances of the Exufiber dressing against an existing
market-leading product, which is a mainstream clinical
choice. Both types of primary dressings interacted with
the MBS dressing, which served here as the secondary
dressing applied to the robotic phantom. The Exufiber
dressing demonstrated good sorptivity and capillary
action, that is, adequate transfer of fluids to the second-
ary MBS dressing (for different body postures), so that
fluids are being wicked away from the wound and into
the secondary dressing. In contrast, the other market-
leading dressing acted more as a “plug,” which, in real-
world conditions, may cause hyper-hydration of the
wound or peri-wound skin maceration, irritation, and
infection (some or all of the above) because of accumula-
tion of exudate fluids under or around the dressing when
it is saturated (ie, a “pooling” effect). We further found
that, for a supine posture, that is, when the wound bed
was fully loaded by simulated bodyweight forces and
where gravity forces aligned with the direction of the
exudate flow, there was an even stronger effect of fluid
transfer from the Exufiber dressing to the secondary MBS
dressing (Figure 3C). Finally, we found that the Exufiber
dressing was more able to resist pulling forces, and its
mechanical strength was five times better than that of
the comparison (Figures 4 and 5), which is critically
important for the dressing to not leave debris when being
pulled out of the wound bed upon removal. Any dressing
debris that is left behind in the wound bed can trigger a
local inflammatory reaction (known as a “foreign-body-
reaction”) and, thereby, consume inflammatory system
resources that are needed for healing the wound at
that time.
In closure, there are currently thousands of dressing
products and brands available for clinicians to choose
from in their wound care practice; these products belong
in diverse classes, have distinguished design concepts
and mechanisms of action, and also vary in their cost per
item and recommended replacement time (which also
affects the cost of use). It is up to the clinician to select
the suitable dressing for the specific patient, clinical case,
and healing phase, which is not an easy task.41 Our pre-
sent work underpins some of the fundamental consider-
ations for adequately choosing a dressing, with a focus on
the function of a primary-secondary dressing system as a
synergistic one. Here, we report a quantitative and rigor-
ous bioengineering evaluation of two dressing products,
which has been performed in a clinically relevant simu-
lated wound environment. The two tested dressing prod-
ucts differ in their micro-architectural design and,
consequently, in the fluid-structure interactions that
occur in their construction, which result in fundamen-
tally different performances. Specifically, the Exufiber
dressing, made of tightly entangled PVA fibres, demon-
strated greater sorptivity and, therefore, superior reten-
tion performances in all the simulated lying positions
compared with the CMC-containing product. In the
mechanical tests of dressings post-simulated use, the
Exufiber dressing exhibited significantly better durability,
which is again a consequence of its densely packed aniso-
tropic PVA fibre arrangement.
Our novel laboratory approach paves the way for an
objective, quantitative, and standardised testing of wound
dressings in all aspects of exudate management, for
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example, efficacy research and product evaluation includ-
ing systematic comparisons for both classic dressing
designs and other advanced wound filler materials. Our
robotic phantom and standardised experimental proto-
cols incorporate clinically relevant scenarios and consider
interactions of different dressing technologies with rele-
vant clinical practice. Our approach and technology can
therefore support a more informed decision-making pro-
cess, for example, regarding the purchase of dressing
products by clinicians and administrators, or where it
concerns the prescription of dressings to individuals
based on their health and wound conditions. Impor-
tantly, the present work is also a cornerstone for the
development of testing standards for wound dressings.
Such testing standards should incorporate the clinical
practice aspects and a high degree of realism of the test-
ing (in order to mimic the real-life use of dressings) while
also facilitating the reproducibility and precision of labo-
ratory tests. Finally, as we continue to improve our
robotic phantom technology for testing dressings and per-
haps, in the future, negative pressure wound therapy sys-
tems as well, we already envision a second generation of
our robotic phantom system. Such a second-generation
robotic phantom should better replicate rough wound
surfaces, undermining conditions, sticky or sloughy
wound beds, and perhaps even incorporate bacterial
growth features, including a module to monitor the
growth of a bacteria model (eg, Escherichia coli or
Bifidobacterium) or its elimination in the simulated
wound. Through present and future innovative robotic
phantom studies, we expect to change the behaviour of
clinicians and administrators with regard to purchase
and prescription of wound dressings, particularly by facil-
itating informed decisions and development of testing
standards, which will certainly contribute to basing dress-
ing selection on quantitative research evidence rather
than marketing assertions, thus ultimately improving
patient care globally.
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ENDNOTE
* Currently used testing methods relevant to the present study
(reviewed comprehensively by Thomas & Uzun, 2019) are
designed to measure simple aspects of absorbency as defined, for
example, in the British (2002) Standard.22 Typically, such a test
would compare the mass of a dressing after water absorption (M2)
to its dry mass (M1) and calculate the dimensionless mass change
(M2 − M1)/M1, an oversimplification that neglects the effects of
multiple relevant clinical factors.
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